Open Access<p>Therapeutic targets of hypercholesterolemia: HMGCR and LDLR</p>
Author(s) -
Shizhan Ma,
Wenxiu Sun,
Ling Gao,
Shudong Liu
Publication year - 2019
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s219013
Subject(s) - ldl receptor , familial hypercholesterolemia , cholesterol , reductase , hmg coa reductase , medicine , endocrinology , lipoprotein , homeostasis , chemistry , biology , enzyme , biochemistry
Cholesterol homeostasis is critical and necessary for the body's functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low-density lipoprotein cholesterol receptor (LDLR) are major points of control in cholesterol homeostasis. We summarize the regulatory mechanisms of HMGCR and LDLR, which may provide insight for new drug design and development.